apolipoprotein ai milano also naturally occurring mutated variant apolipoprotein protein found human hdl lipoprotein particle carries cholesterol tissues liver associated protection cardiovascular disease apoai milano first identified dr cesare sirtori milan also demonstrated presence significantly reduced cardiovascular disease even though caused reduction hdl levels increase triglyceride apoai milano mutation found university milan researchers investigation low hdl high triglyceride phenotype exhibited valerio dagnoli limone sul garda small village northern limone inhabitants time blood tests run entire population village mutation found present local mutation traced one man giovanni born village passed characterised replacement arginine cysteine position mutation known single nucleotide polymorphism snp nomenclature researchers cedarssinai medical center showed injection synthetic version mutant apoai rabbits mice could reverse vascular plaque apo ai milano shown reduce atherosclerosis animal models small phase human trial recombinant adenoassociated virus mediated apo ai milano gene therapy combination lowcholesterol diet induces rapid significant regression atherosclerosis first examination using mutant apoai humans conducted three way collaboration university milan companies pharmacia upjohn focusing treatment apoai milano trial published jama first published placebo controlled dose level trial humans secondary prevention trial included individuals presented participating hospital unstable angina agreed consent rigorous trial well beyond usual clinical practice testing treatment testing whether hdl protein variant effective animals would also work humans trial initiated steven nissen cleveland clinic prompting roger newton esperion examine effects mutant protein using intravascular ultrasound esperion provided protein code named duration due potential efficacy speculated development synthetic apoai milano might key factor eradicating coronary heart esperion therapeutics high tech venture capital startup demonstrated efficacy animals humans spending many millions dollars several years conduct single human trial showed impressive rapid efficacy ivus coronary arteries however course project produced enough apoai milano partially treat thirty fortyfive people randomized trial giving one weekly dose five weeks results trial published jama november hoping develop effective treatment current product lipitor pfizer purchased internalized esperion shortly jama published results apo ai milano trialcitation needed currently drugs based milano commercially available rights apoai milano acquired pfizer clinically known pfizer move trials forward probably complex protein expensive produce must administered intravenously limiting application compared oral pfizer cetp agent torcetrapib failed large human safety trial decided exit cardiovascular market though continue market lipitor aggressively esperion divested pfizer back business continue work hdl mimetic company established agreement transgenrx protein calgarybased sembiosys genetics inc biotechnology company using safflower develop commercial quantities apoai milanocitation needed october sembiosys genetics signed multiproduct commercialization platform collaboration agreement tasly pharmaceuticals tianjin china may sembiosys terminated operations announced tasly terminated december medicines company announced entered exclusive worldwide licensing agreement pfizer inc apoai milano renamed july medicines company signed pharmaceutical development manufacturing contract octoplus netherlandsbased drug delivery drug development company perform process development clinical manufacturing trial study failed produce significant enough results compared drugs tested medicines company discontinued development cardigant medical los angelesbased biotech company worked commercialize apoai milano treat various vascular diseases new trials commercialisation reported web domain company website httpwwwcardigantcom archived wayback machine expired httpsenwikipediaorgwikiapoaimilano